SELLAS Life Sciences Group, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on the stock and has a $7.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy has given his Buy rating due to a combination of factors including the financial stability and promising clinical developments of SELLAS Life Sciences Group. The company reported a net loss for the third quarter of 2025 but has secured additional funding through warrant exercises, providing financial runway into 2027. This financial stability supports the ongoing pivotal Phase 3 study of galinpepimut-S (GPS), a WT1-targeting immunotherapy, which is anticipated to yield top-line data by the end of 2025. The outcome of this study is crucial as it could indicate a therapeutic benefit in a setting with poor prognosis, thus potentially enhancing the stock’s value.
Additionally, the positive data from the Phase 2 program for SLS009, a CDK9 inhibitor, in relapsed/refractory AML supports its advancement into a first-line treatment trial. This progression aligns with current trends in drug development for AML, aiming to improve response durability in first-line patients. The upcoming presentation of data at the American Society of Hematology meeting is expected to further build awareness and support for these initiatives, reinforcing the Buy rating.
SLS’s price has also changed slightly for the past six months – from $1.410 to $1.460, which is a 3.55% increase.